References

1. Kane, JM Clinical efficacy of clozapine in treatment-refractory schizophrenia: an overview. Br J Psychiatry (1992), 160(17): 41–45.

2. Henderson, DC, Cagliero, E, Gray, C, Nasrallah, RA, Hayden, DL, Schoenfeld, DA, and Goff, DC Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. Am J Psychiatry (2000), 157(6): 975–981 .

3. Allison, DB, Mentore, JL, Heo, M, Chandler, LP, Cappelleri, JC, Infante, MC, and Weiden, PJ Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry (1999), 156(11): 1686–1696 .

4. Umbricht, DSG, Pollack, S, and Kane, JM Clozapine and weight gain. The Journal of Clinical Psychiatry (1994), 59(B): 157–160.

5. Bustillo, J, Buchanan, R, Irish, D, and Brerer, A Differential effect of clozapine on weight: A controlled study. Am J Psychiatry (1996), 153(6): 817–819 .

6. Lamberti, JS, Bellnier, T, and Schwarzkopf, SB Weight gain among schizophrenic patients treated with clozapine. Am J Psychiatry (1992), 149(5): 689–690 .

7. Cohen, S, Chiles, J, and MacNaughton, A Weight gain associated with clozapine. Am J Psychiatry (1990), 147: 503–504 .

8. Bai, YM, Lin, CC, Chen, JY, and Lin, CY Weight gain among patients on clozapine. Psychiatr Serv (1999), 50(5): 704–705 .

9. Leadbetter, R, Shutty, M, Pavalonis, D, Vieweg, V, Higgins, P, and Downs, M Clozapine-induced weight gain: Prevalence and clinical relevance. Am J Psychiatry (1992), 149: 68–72 .

10. Pi-Sunyer, F Medical hazards of obesity. Annals of Internal Medicine (1993), 119(7): 655–660 .

11. US Modafinil in Narcolepsy Study Group: Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy US Modafinil in Narcolepsy Multicenter Study Group. Ann Neurol (1998), 43(1): 88–97 .

12. Jasinski, DR, and Kovacevic-Ristanovic, R Evaluation of the abuse liability of modafinil and other drugs for excessive daytime sleepiness associated with narcolepsy. Clin Neuropharmacol (2000), 23(3): 149–156 .

13. Jasinski, DR An evaluation of the abuse potential of modafinil using methylphenidate as a reference. J Psychopharmacol (2000), 14(1): 53–60 .

14. Nishino, S, Mao, J, Sampathkumaran, R, and Shelton, J Increased dopaminergic transmission mediates the wake-promoting effects of CNS stimulants. Sleep Res Online (1998), 1(1): 49–61 .

15. Scammell, TE, Estabrooke, IV, McCarthy, MT, Chemelli, RM, Yanagisawa, M, Miller, MS, and Saper, CB Hypothalamic arousal regions are activated during modafinil-induced wakefulness. J Neurosci (2000), 20(22): 8620–8628 .

16. Wisor, JP, Nishino, S, Sora, I, Uhl, GH, Mignot, E, and Edgar, DM Dopaminergic role in stimulant-induced wakefulness. J Neurosci (2001), 21(5): 1787–1794 .

17. Dinges, DF, and Weaver, TE Effects of modafinil on sustained attention performance and quality of life in OSA patients with residual sleepiness while being treated with nCPAP. Sleep Med (2003), 4(5): 393–402 .

18. Narendran, R, Young, CM, Valenti, AM, Nickolova, MK, and Pristach, CA Is psychosis exacerbated by modafinil?. Arch Gen Psychiatry (2002), 59(3): 292–293 .

19. Dequardo, JR Modafinil-associated clozapine toxicity. Am J Psychiatry (2002), 159(7): 1243–1244 .